Inovio Pharmaceuticals, Inc. INO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
11/100
Weak

Ranked against 712 peers in Biotechnology

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates … Full INO analysis →

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 3.9th percentile with high volatility suggests weak pricing power or commoditized products.
  • Elevated Debt Risk Debt serviceability is weak (score 0.17), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
5
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where INO ranks in Biotechnology

Inovio Pharmaceuticals, Inc. ranks #643 of 713 scored companies in Biotechnology by moat score — the top 90%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
639 Applied Therapeutics, Inc. APLT 12/100 Weak
640 BioCardia, Inc. BCDA 12/100 Weak
641 Cingulate Inc. CING 12/100 Weak
642 Cingulate Inc. Warrants CINGW 12/100 Weak
643 Inovio Pharmaceuticals, Inc. INO 11/100 Weak
644 Aditxt, Inc. ADTX 11/100 Weak
645 CNS Pharmaceuticals, Inc. CNSP 10/100 Weak
646 Tharimmune, Inc. THAR 9/100 Weak
647 FibroBiologics, Inc. FBLG 9/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How INO scores on the Corporate Default defenses

Pricing Power

Score 5 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 4 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 16 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 22 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 14 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 4 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding INO's moat

What is Inovio Pharmaceuticals, Inc.'s moat score?

Inovio Pharmaceuticals, Inc. (INO) scores 11 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #643 of 713 scored companies in Biotechnology, the top 90%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (22/100) and its weakest is Cost Advantage (4/100).

How does Inovio Pharmaceuticals, Inc. compare with other Biotechnology companies?

Inovio Pharmaceuticals, Inc. ranks #643 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Cingulate Inc. Warrants (CINGW) at 12 just above it and Aditxt, Inc. (ADTX) at 11 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Inovio Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Inovio Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and INO scores: Pricing Power (5), Cost Advantage (4), Customer Stickiness (16), Capital Efficiency (22), Resilience (14), Scale & Market Position (4). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000